The government has announced over £20 million to improve prostate cancer research and treatment.
Men at the highest risk of prostate cancer are set to benefit from research to find the best screening strategy and more treatment choices.
One prostate cancer screening trial will be expanded so all eligible Black men will be invited to take part.
The TRANSFORM study is testing the best ways to detect prostate cancer earlier and save more lives, while avoiding unnecessary treatment and the associated harms.
The change recognises that Black men face a higher risk of prostate cancer and aims to build the evidence needed to find the best screening strategy and tackle long-standing inequalities.
Access to focal therapies will be expanded, giving men greater choice about their options when they receive a new diagnosis.
The government has accepted a recommendation from the independent UK National Screening Committee (UK NSC) to introduce England’s first targeted prostate cancer screening programme. Men who carry the BRCA2 gene variant and have a family history of prostate, breast, pancreatic or ovarian cancer will be offered a PSA test every two years between the ages of 45 and 61.
Health and Social Care Secretary, James Murray said: "This is a major step forward in how we tackle prostate cancer - focusing on those most at risk, improving the treatments available, and backing the research we need to close the evidence gaps and save lives.
"We’re following the science to make sure men get earlier answers and better care, and to avoid doing unnecessary harm.
"By investing in research through trials such as TRANSFORM, we’re building a fairer, more effective prostate cancer screening system for the futures."
Deputy Prime Minister, David Lammy, said: "Tackling prostate cancer is personal for me. I’ve got two brothers living with the disease, and I’ve seen firsthand the toll it takes on individuals and their loved ones.
"Helping more Black men take part in this research is about saving lives, closing deadly inequalities and making sure we understand what works best for those most at risk."
